Clinical Trials
Validating what the body of research suggests: that a patient’s underlying biology, not a one-size-fits-all protocol, should guide their treatment.
Same Diagnosis. Different Biology.
For decades, clinical trials for acute conditions like sepsis, ARDS, and acute kidney injury have grouped patients by syndrome. But a shared diagnosis doesn’t mean shared biology. A treatment that helps one biological subset of patients may do nothing, or cause harm, in another. When different populations are pooled into a single trial, real treatment effects disappear.
Precision Where Broad Trials Failed
The Right Patients, for Drugs That Already Exist
Patient heterogeneity is exactly the kind of problem AI is suited to solve. Our AI-powered models can identify which patients would respond to a treatment that may already exist, finding value in therapies that may have failed in a broader trial simply because the right population was never isolated.
That means we can run large-scale trials more efficiently and more quickly, building on work that’s already been done. For pharma companies that have already invested in a therapy now sitting on the shelf, it’s a fast, low-investment path to clinical use.
More than a Traditional CRO
One Clinical Trial Network. Four Functions.
Our trials — conducted with a growing network of leading academic medical centers — are designed to directly address the issue of patient heterogeneity: tapping into individual patient biology to determine which patients will respond to which treatments, and training our models to recognize those patterns in future patients.
And because our platform is integrated directly with hospital EHR systems, research sites can move directly into subsequent clinical trial enrollment without the standard site-activation and integration timeline generally required for every new trial.
The Prenosis difference? Our infrastructure is designed for end-to-end development and delivery of targeted treatment:
Generate the proprietary biological data that powers our models,
Uncover new biologically defined patient populations,
Run the randomized trials that validate what we find, and
Identify the right patients in real time to deliver targeted treatment.
Treatment, Tailored to Biology
Transforming Clinical Trials for Acute Illness
Clinical trials for acute conditions like sepsis, ARDS, pneumonia, acute kidney injury, and acute heart failure have largely failed to find their mark, until now. Prenosis pairs a growing biological map with AI to select the right patients for the right trial. And with each study, that map grows, giving our platform more data to identify eligible patients, manage samples, and activate the next trial faster.
Steroid Therapy Optimization for Prevention of Acute Respiratory Distress Syndrome
A prospective, randomized clinical trial testing whether AI-Biomarkers can identify which patients with severe respiratory infection will benefit from corticosteroid therapy.
Observational Trial in Acute Respiratory Distress Syndrome
An observational study pairing patient biology with outcomes in ARDS, expanding the biobank that helps us uncover new, treatable patient populations.